Omid Hamid, MD, on Improving Duration of Response in Refractory Melanoma With Lifileucel

"Lifileucel is a 1-time therapy. The toxicity is manageable and usually related to the preconditioning or the IL2. So, what you have is the ability to give a viable option to our patients that is a1-time option and can give durability of response.”

The investigational autologous tumor infiltrating lymphocyte (TIL) therapy lifileucel (Iovance Biotherapeutics) has demonstrated encouraging efficacy and a manageable safety profile in pooled data from 2 cohorts of patients with heavily pretreated advanced melanoma in the phase 2 C-144-01 (NCT02360579) clinical trial. Data from the study were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, November 8-12, 2022, in Boston, Massachusetts, by Amod A. Sarnaik, MD, FACS, Moffitt Cancer Center.

Investigators found that lifileucel had an objective response rate of 31.4% in the 2 cohorts, with 9 complete responses and 39 partial responses. Median duration of response(DOR) was not reached at a median follow up of 36.5 months, and 41.7% of responding patients had a DOR of 24 months or more. Median overall survival (OS) was 13.9 months, and the 12-month OS rate was 54% (95% CI: 45.6%, 61.6%)

CGTLive spoke with the study's co-author Omid Hamid, MD, chief, research and immunotherapy, Cedars-Sinai - The Angeles Clinic and Research Institute, to learn more about the C-144-01 study and the lifileucel TIL therapy. He discussed the advantages of the therapy in melanoma and how the research forwards progress for immunotherapy in solid tumors as a whole.

Click here to read more coverage of SITC 2022.

REFERENCE

Sarnaik A. Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study). Presented at: Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting November 8-12, 2022; Boston, Massachusetts. Abstract #789